

# Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)

Technology appraisal guidance

Published: 28 October 2015

[www.nice.org.uk/guidance/ta362](https://www.nice.org.uk/guidance/ta362)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable. This is because Celgene did not provide an evidence submission.

## Information

If NHS organisations wish to consider paclitaxel for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-1510-1